# PULSE Registry: for Patients Receiving Lutetium (177Lu) Vipivotide Tetraxetan

> **NCT07484269** · — · NOT_YET_RECRUITING · sponsor: **Novartis Pharmaceuticals** · enrollment: 753 (estimated)

## Conditions studied

- Metastatic Prostate Cancer

## Interventions

_None listed._

## Key facts

- **NCT ID:** NCT07484269
- **Lead sponsor:** Novartis Pharmaceuticals
- **Sponsor class:** INDUSTRY
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** NOT_YET_RECRUITING
- **Start date:** 2026-08-01
- **Primary completion:** 2031-07-31
- **Final completion:** 2031-07-31
- **Target enrollment:** 753 (ESTIMATED)
- **Last updated:** 2026-03-20


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07484269

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07484269, "PULSE Registry: for Patients Receiving Lutetium (177Lu) Vipivotide Tetraxetan". Retrieved via AI Analytics 2026-05-25 from https://api.ai-analytics.org/clinical/NCT07484269. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*